Effect of tofacitinib exposure in utero and during breastfeeding on the immune status of exposed child
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F25%3A00085550" target="_blank" >RIV/00023001:_____/25:00085550 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/25:10496726 RIV/00216208:11130/25:10496726 RIV/00064203:_____/25:10496726
Result on the web
<a href="https://academic.oup.com/ecco-jcc/article/19/4/jjaf049/8092496#google_vignette" target="_blank" >https://academic.oup.com/ecco-jcc/article/19/4/jjaf049/8092496#google_vignette</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/ecco-jcc/jjaf049" target="_blank" >10.1093/ecco-jcc/jjaf049</a>
Alternative languages
Result language
angličtina
Original language name
Effect of tofacitinib exposure in utero and during breastfeeding on the immune status of exposed child
Original language description
Background and Aims Janus kinase (JAK) inhibitors, such as tofacitinib, are potent anti-inflammatory agents used in the treatment of ulcerative colitis (UC). Current guidelines recommend avoiding their use during pregnancy due to safety concerns, as well as during breastfeeding due to the potential excretion into breast milk.Methods This case report describes the impact of in utero exposure to tofacitinib during pregnancy and subsequent exposure via breastfeeding on the immune development of the exposed infant.Results A 37-year-old woman with UC, who was being treated with tofacitinib and vedolizumab, became pregnant and continued both medications, with the tofacitinib dosage reduced from 10 to 5 mg BID at gestational week 28. The infant was born healthy, with normal growth and development, and received all scheduled non-live vaccinations. At 15 months, immune parameters-including response to vaccination-were evaluated. The results showed normal immunoglobulin levels and an adequate serologic response to vaccination, with no signs of immune dysfunction.Conclusions This case suggests that prolonged prenatal and postnatal exposure to tofacitinib may not adversely affect infant immune development. However, caution is advised due to the limited number of documented cases. Further research is needed to fully understand the long-term implications of JAK inhibitor exposure during pregnancy and breastfeeding.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30219 - Gastroenterology and hepatology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Crohn's and colitis
ISSN
1873-9946
e-ISSN
1876-4479
Volume of the periodical
19
Issue of the periodical within the volume
4
Country of publishing house
GB - UNITED KINGDOM
Number of pages
4
Pages from-to
"art. no. jjaf049"
UT code for WoS article
001470606800006
EID of the result in the Scopus database
2-s2.0-105003205135